Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2000
08/15/2000US6103874 Human KDEL receptor
08/15/2000US6103869 Isolated polypeptide with a mutation at amino acid 464, 465, and/or 467 resulting in dominant negative inhibition of transforming growth factor-beta signaling; therapy and diagnosis of related diseases
08/15/2000US6103710 Glucocorticoid response elements
08/15/2000US6103705 Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
08/15/2000US6103527 Nucleotide sequence from gene expressed in proliferating endothelial cells; for controlled gene expression especially for transgenic tissues and gene therapy
08/15/2000US6103519 Recombinant dna including coding sequence and regulatory sequence for expression of l protein with modified or deleted regions; for hepatitis vaccines
08/15/2000US6103507 Protein used to raise an immunological response against a bacteria; bactericides
08/15/2000US6103494 Nucleotide sequences which code protein associated with immmune response; for the detection of flea allergy dermatitis; for the detection of modulators of immune response
08/15/2000US6103484 Method for immunodiagnosis of heartworm in mammals
08/15/2000US6103244 Containing a heterologous insert encoding an immunogenic protein, wherein said insert was molecularly cloned directly into the viral genome into a unique restriction endonuclease cleavage site
08/15/2000US6103243 Oral vaccines
08/15/2000US6103239 Modified HGP-30 heteroconjugates, compositions and methods of use
08/15/2000US6103238 Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
08/15/2000US6103237 More stable to purification than wild type mature hk2 polypeptide.
08/15/2000US6103236 In which a compound having an affinity for a target cell is bound to a toxin through a spacer consisting essentially of polyalkylene glycol and a dipeptide.
08/15/2000US6103234 Antibody to an inflammatory cytokine, said inflammatory cytokine comprising a mature macrophage inflammatory protein -2 (mmip-2)
08/15/2000US6103233 Cellular and serum protein anchors and conjugates
08/15/2000CA2196431C Icam-4 materials and methods
08/15/2000CA2153391C Inducing cytotoxic t lymphocyte responses
08/15/2000CA2151409C Formulation for stabilizing human immunoglobulins
08/15/2000CA2142861C Novel uses of il-4 and/or il-10, and antibodies against the same
08/15/2000CA2046601C Production and use of anthelmintic agents and protective immunogens
08/15/2000CA2034484C Radioimmunotherapy using .alpha.-particles emission
08/11/2000WO2000047225A2 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
08/10/2000WO2000046390A1 T helper cell epitopes
08/10/2000WO2000046381A1 Recombinant expression of heterologous nucleic acids in protozoa
08/10/2000WO2000046373A1 Diagnostic and protective antigen gene sequences of ichthyophthirius
08/10/2000WO2000046365A1 Advanced antigen presentation platform
08/10/2000WO2000046359A2 Medicament
08/10/2000WO2000046352A1 Human t cell effectors expressing cd86 molecule and therapeutic use thereof
08/10/2000WO2000046344A2 Non-stochastic generation of genetic vaccines and enzymes
08/10/2000WO2000046251A2 Human polyclonal antibodies from transgenic nonhuman animals
08/10/2000WO2000046248A1 Use of agonists or antagonists of mip-3a in therapy
08/10/2000WO2000046244A1 cDNA SEQUENCE OF AN INTERACTOR FANCIP1 OF THE FANCONI ANAEMIA PROTEIN OF COMPLEMENTATION GROUP A
08/10/2000WO2000046242A2 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI)
08/10/2000WO2000046240A2 Polypeptides involved in immune response
08/10/2000WO2000046147A2 Therapeutic calcium phosphate particles and methods of manufacture and use
08/10/2000WO2000045851A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
08/10/2000WO2000045849A2 Use of cationic lipids to generate anti-tumor immunity
08/10/2000WO2000045847A1 Novel mucosal delivery system
08/10/2000WO2000045844A1 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
08/10/2000WO2000045842A2 Methods for human allografting
08/10/2000WO2000045841A2 Human papilloma virus vaccine formulations
08/10/2000WO2000045840A1 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
08/10/2000WO2000045837A1 Novel use within transplantation surgery
08/10/2000WO2000045835A1 Vascular endothelial growth factor-2
08/10/2000WO2000045823A1 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
08/10/2000WO2000045792A1 Hydrogel particle formulations
08/10/2000WO2000045770A2 Compressed lecithin preparations
08/10/2000WO2000033861A3 Pharmaceutical compositions containing protein-disulfide isomerases
08/10/2000WO2000029008A3 Hiv-specific t-cell induction
08/10/2000WO2000026239A3 $i(chlamydia) antigens and corresponding dna fragments and uses thereof
08/10/2000WO2000025827A3 Dna molecules encoding muc-1 and use thereof in tumor vaccination
08/10/2000WO2000024773A3 Inhibition of transglutaminase-mediated microbial infection of a mammalian host
08/10/2000WO2000016746A8 Immunogenic liposome compositions
08/10/2000WO2000013706A8 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
08/10/2000WO2000010599A8 IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
08/10/2000WO2000010588A9 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
08/10/2000WO2000006197A8 Combined vaccine for immunoprophylaxis against viral hepatitis b and d, tetanus and diphtheria
08/10/2000WO1999008706A8 Recombinant porcine adenovirus vector
08/10/2000DE19904514A1 Antiviral agent, e.g. vaccine, antibody, agent that inhibits viral replication, transcription or translation, useful for preventing or treating tumors (or conditions which may become tumorous) associated with viral infections
08/10/2000CA2492661A1 Non-stochastic generation of genetic vaccines and enzymes
08/10/2000CA2362126A1 B7rp-1 polypeptides
08/10/2000CA2361658A1 T helper cell epitopes
08/10/2000CA2361615A1 The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
08/10/2000CA2361601A1 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
08/10/2000CA2361555A1 Hydrogel particle formulations
08/10/2000CA2361539A1 Compressed lecithin preparations
08/10/2000CA2361459A1 Use of cationic lipids to generate anti-tumor immunity
08/10/2000CA2361421A1 Therapeutic calcium phosphate particles and methods of manufacture and use
08/10/2000CA2360942A1 Preparations for preventing and/or treating a tissue change of mesenchymal origin
08/10/2000CA2360688A1 Human t cell effectors expressing cd86 molecule and therapeutic use thereof
08/10/2000CA2359469A1 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
08/09/2000EP1026253A2 Expression of exogenous polynucleotide sequences in a vertebrate
08/09/2000EP1026246A1 Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
08/09/2000EP1026245A1 Antigen protein and nucleic acid coding for said protein
08/09/2000EP1026238A2 Cloned glutamic acid decarboxylase
08/09/2000EP1026237A2 Tau/neurofilament protein kinases pk40 & pk36
08/09/2000EP1025856A2 Methods for modulating T Cell unresponsiveness
08/09/2000EP1025853A2 Pharmaceutical composition containing S-nitroso-heme proteins and use thereof
08/09/2000EP1025849A1 Methods for detection and treatment of individuals having abnormal cells expressing HLA-A2/tyrosinase peptide antigens
08/09/2000EP1025840A2 Oral drug compositions and methods
08/09/2000EP1025244A2 NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
08/09/2000EP1025233A2 Novel modified nucleic acid sequences and methods for increasing mrna levels and protein expression in cell systems
08/09/2000EP1025231A1 Robo: a family of polypeptides and nucleic acids involved in nerve cell guidance
08/09/2000EP1025227A2 Human toll homologues
08/09/2000EP1025223A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
08/09/2000EP1025216A1 Transgenic animal models for cardiac hypertrophy and uses thereof
08/09/2000EP1025211A2 Hyaluronan synthase gene and uses thereof
08/09/2000EP1025209A1 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
08/09/2000EP1025122A1 Fibroblast growth factor with hepatocyte proliferation activity
08/09/2000EP1025121A1 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE $g(b)-AMYLOID PEPTIDE OR ITS PRECURSOR
08/09/2000EP1025082A1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
08/09/2000EP1024836A1 Method of delivering genes to antigen presenting cells of the skin
08/09/2000EP1024834A2 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
08/09/2000EP1024831A2 Application of tnf antagonists as medicaments for treating septic diseases
08/09/2000EP1024830A1 Antigen vectors in the form of multilamellar vesicles
08/09/2000EP1024829A1 Tolerogenic fragments of natural allergens
08/09/2000EP1024828A1 NOVEL pheS (BETA)
08/09/2000EP1024827A1 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
1 ... 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 ... 1823